Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Therapeutic Efficacy Assessment of Pyronaridine-Artesunate (Pyramax) and New Drug Combinations With Atovaquone-Proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Cambodia

Next Previous
Search
Trial Profile

Multicenter Therapeutic Efficacy Assessment of Pyronaridine-Artesunate (Pyramax) and New Drug Combinations With Atovaquone-Proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Cambodia

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Artesunate/pyronaridine (Primary) ; Artesunate/mefloquine; Atovaquone/proguanil
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Acronyms APACT

    • Most Recent Events

    • 01 Mar 2021 Planned End Date changed from 30 Jun 2021 to 30 Dec 2022.
    • 01 Mar 2021 Planned primary completion date changed from 30 Dec 2020 to 30 Aug 2022.
    • 23 Dec 2020 Results of subanalysis assessing the Selection of cytochrome b mutants is rare among Plasmodium falciparum patients failing treatment with atovaquone-proguanil in Cambodia, published in the Antimicrobial Agents and Chemotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top